• J P Pfammatter, F P Stocker, J W Weber, M Fasnacht, B Friedli, J Günthard, and M Payot.
• Abteilungen pädiatrische Kardiologie, Universitäts-Kinderkliniken, Bern.
• Swiss Med Wkly. 1993 Oct 9; 123 (40): 1870-4.

AbstractParoxysmal supraventricular tachycardia is the most frequent significant arrhythmia in the pediatric age group, especially in the first year of life. In neonates and infants there are important limitations for the commonly used drugs such as verapamil and digitalis. In an open Swiss multicentre study we treated 19 children with a total of 29 episodes of tachycardia by means of adenosine i.v. as the drug of first choice. 76% of all the tachycardias were converted, whereas the success rate was 87% if only tachycardias with atrioventricular reentry were considered. The important advantage of adenosine lies in its very short half-life of about 15 seconds, which means that the rare relevant, and the more common mild, side effects are quite limited in duration. A major disadvantage are recurrences in about one third of cases. We conclude that adenosine is an efficient and safe treatment for paroxysmal supraventricular tachycardia in the whole pediatric age group including neonates and infants.

16 keywords...

hide…